Skip to main content
Livermore
Livermore
ZHEN

VR Adviser, LLC

SEC CIK
0001615982
Latest filing
Aug 14, 2026

Holdings in Q3 2023

Holdings as of Sep 30, 2023, filed Nov 14, 2023. Long positions only; changes compare share counts with Q2 2023.

Institution overview
Positions
37
+7 vs. Q2 2023
Portfolio value
$949.9M
+$324.6M (+51.9%) vs. Q2 2023
Filed
Nov 14, 2023
SEC
Holdings of VR Adviser, LLC in Q3 2023
SecurityClassSharesValue% of portfolioShare changeActionHistory
APGEApogee Therapeutics, Inc.COM8,493,321$180.9M19.0%+8,493,321NewHistory
RYZBRayzeBio, Inc.COM4,016,847$89.2M9.4%+4,016,847NewHistory
VRDNViridian Therapeutics, Inc.COM3,082,622$47.3M5.0%00.0%UnchangedHistory
COGTCogent Biosciences, Inc.COM4,684,167$45.7M4.8%+350.0%AddedHistory
TSHATaysha Gene Therapies, Inc.COM SHS14,444,444$45.6M4.8%+14,444,444NewHistory
MRUSMerus N.V.COM1,726,214$40.7M4.3%00.0%UnchangedHistory
ELVNEnliven Therapeutics, Inc.COM2,954,902$40.4M4.2%+724,775+32.5%AddedHistory
FDMT4D Molecular Therapeutics, Inc.COM3,000,000$38.2M4.0%00.0%UnchangedHistory
PHVSPharvaris N.V.COM1,563,513$32.6M3.4%+237,313+17.9%AddedHistory
CABACabaletta Bio, Inc.COM1,973,253$30.0M3.2%+20.0%AddedHistory
KALVKalVista Pharmaceuticals, Inc.COM2,916,667$28.1M3.0%00.0%UnchangedHistory
GHRSGH Research PLCORDINARY SHARES2,744,125$27.6M2.9%−773,000−22.0%ReducedHistory
HLVXHilleVax, Inc.COM2,037,313$27.4M2.9%+2,037,313NewHistory
SVRASavara IncCOM7,184,865$27.2M2.9%+833,334+13.1%AddedHistory
RYTMRhythm Pharmaceuticals, Inc.COM1,090,000$25.0M2.6%00.0%UnchangedHistory
AMAMAmbrx Biopharma Cayman, Inc.SPONSORED ADS2,070,000$23.8M2.5%−414,960−16.7%ReducedHistory
TVTXTravere Therapeutics, Inc.COM2,623,677$23.5M2.5%+2,623,677NewHistory
DYNDyne Therapeutics, Inc.COM2,173,913$19.5M2.1%00.0%UnchangedHistory
CELCCelcuity Inc.COM2,105,386$19.2M2.0%00.0%UnchangedHistory
TERNTerns Pharmaceuticals, Inc.COM3,092,273$15.6M1.6%+119,404+4.0%AddedHistory
MRSNMersana Therapeutics, Inc.COM11,328,000$14.4M1.5%+11,328,000NewHistory
APLTApplied Therapeutics, Inc.COM5,658,034$14.1M1.5%00.0%UnchangedHistory
ORICOric Pharmaceuticals, Inc.COM2,142,856$13.0M1.4%00.0%UnchangedHistory
DNTHDianthus Therapeutics, Inc.COM927,706$12.7M1.3%+927,706NewHistory
ADVMAdverum Biotechnologies, Inc.COM6,573,300$9.86M1.0%+2,687,054+69.1%AddedHistory
PRAXPraxis Precision Medicines, Inc.COM5,304,410$9.07M1.0%00.0%UnchangedHistory
SLRNACELYRIN, Inc.COM864,332$8.79M0.9%+864,332NewHistory
TRVITrevi Therapeutics, Inc.COM3,422,397$7.46M0.8%00.0%UnchangedHistory
ACRSAclaris Therapeutics, Inc.COM1,040,754$7.13M0.8%00.0%UnchangedHistory
MISTMilestone Pharmaceuticals Inc.COM2,208,812$6.85M0.7%00.0%UnchangedHistory
PLRXPliant Therapeutics, Inc.COM288,949$5.01M0.5%00.0%UnchangedHistory
SGMTSagimet Biosciences Inc.COM SER A515,000$4.53M0.5%+515,000NewHistory
SYRESpyre Therapeutics, Inc.COM295,034$3.61M0.4%+41,305+16.3%AddedConverted for a 1-for-25 splitHistory
LYRALyra Therapeutics, Inc.COM924,170$3.61M0.4%00.0%UnchangedHistory
OLMAOlema Pharmaceuticals, Inc.COM77,042$951.5K0.1%+77,042NewHistory
RLYBRallybio CorpCOM268,532$905.0K0.1%00.0%UnchangedHistory
Affimed N VN01045108COM1,428,571$682.7K0.1%00.0%Unchanged–

Sold out since Q2 2023 (3)

Positions held at the end of Q2 2023 that are gone from this filing.

Positions of VR Adviser, LLC sold out since Q2 2023
SecurityClassShares in Q2 2023Value in Q2 2023% of portfolio in Q2 2023History
THRXTheseus Pharmaceuticals, Inc.COM770,000$7.18M1.1%History
BDTXBlack Diamond Therapeutics, Inc.COM353,629$1.79M0.3%History
AVTXAvalo Therapeutics, Inc.COM NEW1,250,000$444.0K0.1%History